Leerink Partnrs Predicts Natera FY2027 Earnings

Natera, Inc. (NASDAQ:NTRA) – Stock analysts at Leerink Partnrs issued their FY2027 earnings per share (EPS) estimates for shares of Natera in a note issued to investors on Friday, February 28th. Leerink Partnrs analyst P. Souda anticipates that the medical research company will post earnings of ($0.92) per share for the year. The consensus estimate for Natera’s current full-year earnings is ($1.49) per share.

Natera (NASDAQ:NTRA) last announced its earnings results on Thursday, February 27th. The medical research company reported ($0.41) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.42) by $0.01. The firm had revenue of $476.10 million for the quarter, compared to analysts’ expectations of $447.91 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%.

Several other analysts also recently weighed in on NTRA. The Goldman Sachs Group lifted their price target on shares of Natera from $160.00 to $190.00 and gave the company a “buy” rating in a research note on Tuesday, January 28th. Robert W. Baird raised their price target on Natera from $183.00 to $188.00 and gave the company an “outperform” rating in a research note on Friday. Guggenheim lifted their price objective on Natera from $170.00 to $200.00 and gave the company a “buy” rating in a report on Friday, January 17th. Barclays initiated coverage on shares of Natera in a report on Thursday, January 23rd. They set an “overweight” rating and a $200.00 target price on the stock. Finally, Craig Hallum upped their price target on shares of Natera from $121.00 to $157.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. One equities research analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $172.69.

Natera Price Performance

NTRA stock opened at $143.11 on Monday. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33. The stock has a market cap of $18.89 billion, a PE ratio of -81.31 and a beta of 1.66. Natera has a 12 month low of $83.13 and a 12 month high of $183.00. The company has a 50-day moving average price of $167.44 and a 200 day moving average price of $147.35.

Institutional Trading of Natera

A number of hedge funds and other institutional investors have recently made changes to their positions in NTRA. LRI Investments LLC purchased a new stake in Natera in the fourth quarter valued at $29,000. Blue Trust Inc. lifted its holdings in shares of Natera by 104.3% in the 4th quarter. Blue Trust Inc. now owns 190 shares of the medical research company’s stock valued at $30,000 after buying an additional 97 shares during the period. Versant Capital Management Inc boosted its stake in shares of Natera by 345.8% in the fourth quarter. Versant Capital Management Inc now owns 214 shares of the medical research company’s stock worth $34,000 after buying an additional 166 shares during the last quarter. EverSource Wealth Advisors LLC boosted its stake in shares of Natera by 372.9% in the fourth quarter. EverSource Wealth Advisors LLC now owns 331 shares of the medical research company’s stock worth $52,000 after buying an additional 261 shares during the last quarter. Finally, Principal Securities Inc. grew its holdings in Natera by 20.7% during the fourth quarter. Principal Securities Inc. now owns 344 shares of the medical research company’s stock worth $54,000 after acquiring an additional 59 shares during the period. Institutional investors and hedge funds own 99.90% of the company’s stock.

Insider Buying and Selling

In related news, CFO Michael Burkes Brophy sold 43,502 shares of the company’s stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $176.88, for a total value of $7,694,633.76. Following the sale, the chief financial officer now owns 70,629 shares in the company, valued at $12,492,857.52. This represents a 38.12 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider John Fesko sold 669 shares of the firm’s stock in a transaction that occurred on Monday, December 23rd. The stock was sold at an average price of $159.60, for a total transaction of $106,772.40. Following the transaction, the insider now directly owns 114,142 shares of the company’s stock, valued at $18,217,063.20. This represents a 0.58 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 208,299 shares of company stock worth $34,948,265 in the last 90 days. Insiders own 7.60% of the company’s stock.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.